{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:08:29Z","timestamp":1790158109191,"version":"4.1.0"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gastric cancer (GC) remains a major cause of cancer-related mortality, and therapeutic resistance and tumor heterogeneity continue to limit durable responses in advanced disease. Antibody\u2013drug conjugates (ADCs), which combine the target specificity of monoclonal antibodies with highly potent cytotoxic payloads, have emerged as an important component of biomarker-guided therapy. Beyond selective payload delivery, accumulating evidence indicates that ADCs can interact with antitumor immunity through Fc-mediated immune-effector functions, immunogenic tumor-cell death, enhanced antigen presentation, recruitment of effector T cells, and remodeling of the tumor immune microenvironment. In this review, we summarize the structural and pharmacological principles of ADCs and discuss established and emerging targets in GC, including HER2, CLDN18.2, HER3, GCC, TROP2, Nectin-4, EGFR, and MUC1. Particular emphasis is placed on the immunological consequences of ADC treatment and the mechanistic rationale for combining ADCs with immune checkpoint inhibitors. We further discuss tumor heterogeneity, resistance mechanisms, biomarker selection, treatment-related toxicities, and emerging combination strategies. Integrating tumor-antigen biology with immune-contextual features may enable more rational patient selection and therapeutic combinations. Collectively, next-generation ADCs may function not only as targeted cytotoxic agents but also as modulators of antitumor immunity in gastric cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1928576","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:29:50Z","timestamp":1790155790000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody\u2013drug conjugates in gastric cancer: from targeted cytotoxicity to immune modulation"],"prefix":"10.3389","volume":"17","author":[{"given":"Honghua","family":"Su","sequence":"first","affiliation":[{"name":"Department of General Surgery, Kunming Municipal Hospital of Traditional Chinese Medicine, The Third Affiliated Hospital of Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Kunming Municipal Hospital of Traditional Chinese Medicine, The Third Affiliated Hospital of Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayun","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Kunming Municipal Hospital of Traditional Chinese Medicine, The Third Affiliated Hospital of Yunnan University of Chinese Medicine","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-018-0868-0","article-title":"Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma","volume":"22","author":"Mariette","year":"2019","journal-title":"Gastric Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2857","article-title":"Helicobacter pylori: gastric cancer and beyond","volume":"10","author":"Polk","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.059","article-title":"Genetics and molecular pathogenesis of gastric adenocarcinoma","volume":"149","author":"Tan","year":"2015","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)71016-2","article-title":"Familial gastric cancer: genetic susceptibility, pathology, and implications for management","volume":"16","author":"Oliveira","year":"2015","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2211807","article-title":"Helicobacter pylori, homologous-recombination genes, and gastric cancer","volume":"388","author":"Usui","year":"2023","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-443-15609-0.00017-9","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-3726","article-title":"FDA approval summary: Pembrolizumab for the treatment of HER2-positive gastric cancer","volume":"32","author":"Casak","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60643-6","article-title":"Oesophageal carcinoma","volume":"381","author":"Pennathur","year":"2013","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.56735","article-title":"Progress of gastric cancer surgery in the era of precision medicine","volume":"17","author":"Wang","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201914511","article-title":"Targeted engineering of medicinal chemistry for cancer therapy: recent advances and perspectives","volume":"60","author":"Chen","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15750","article-title":"Clinical advances in targeting epigenetics for cancer therapy","volume":"289","author":"Feng","year":"2022","journal-title":"FEBS J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28550","article-title":"KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells","volume":"134","author":"Nakadate","year":"2014","journal-title":"Int J Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.mcr-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.27436","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s135571","article-title":"Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13046-017-0667-1","article-title":"Fate of antibody-drug conjugates in cancer cells","volume":"37","author":"Chalouni","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01072-5","article-title":"Antibody-drug conjugate revolution in breast cancer: the road ahead","volume":"24","author":"Grinda","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1124\/pharmrev.121.000499","article-title":"New technologies bloom together for bettering cancer drug conjugates","volume":"74","author":"Jin","year":"2022","journal-title":"Pharmacol Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv Drug Delivery Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics18080954","article-title":"Linker design in antibody-drug conjugates: balancing stability and drug release","volume":"18","author":"Albino","year":"2026","journal-title":"Pharmaceutics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500262","article-title":"Linker design for the antibody drug conjugates: a comprehensive review","volume":"20","author":"Lei","year":"2025","journal-title":"ChemMedChem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0345-9","article-title":"Boosting therapeutic potency of antibodies by taming Fc domain functions","volume":"51","author":"Kang","year":"2019","journal-title":"Exp Mol Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2018-lb-294","article-title":"Abstract lb-294: synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (MAB) in a syngeneic breast cancer model expressing human HER2","volume":"78","author":"Traore","year":"2018"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/iub.2804","article-title":"The tumor immune microenvironment remodeling and response to HER2-targeted therapy in HER2-positive advanced gastric cancer","volume":"76","author":"Jiang","year":"2024","journal-title":"IUBMB Life"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6765","article-title":"The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression","volume":"12","author":"Jing","year":"2023","journal-title":"Cancer Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2011.03.002","article-title":"Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer","volume":"306","author":"Barok","year":"2011","journal-title":"Cancer Lett"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30111-0","article-title":"Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study","volume":"18","author":"Thuss-Patience","year":"2017","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-00923-7","article-title":"Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric\/gastroesophageal junction cancer","volume":"22","author":"Shah","year":"2019","journal-title":"Gastric Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100814","article-title":"Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma","volume":"3","author":"Zhang","year":"2022","journal-title":"Cell Rep Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbab017","article-title":"Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors","volume":"4","author":"Li","year":"2021","journal-title":"Antib Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-19-0207","article-title":"A novel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine","volume":"18","author":"Le Joncour","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-08-1064","article-title":"High expression of HER3 is associated with a decreased survival in gastric cancer","volume":"14","author":"Hayashi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/jci126598","article-title":"U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation","volume":"130","author":"Haratani","year":"2020","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040483","article-title":"EV20\/NMS-P945, a novel thienoindole based antibody-drug conjugate targeting HER-3 for solid tumors","volume":"13","author":"Capone","year":"2021","journal-title":"Pharmaceutics"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2021.1967080","article-title":"Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials","volume":"10","author":"Kyuno","year":"2022","journal-title":"Tissue Barriers"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2020.02.13","article-title":"Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer","volume":"32","author":"Zhang","year":"2020","journal-title":"Chin J Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101710","article-title":"CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00636-3","article-title":"Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial","volume":"26","author":"Ruan","year":"2025","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1132319","article-title":"Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1158\/1538-7445.am2022-1143","article-title":"ATG-022, an antibody-drug conjugate targeting Claudin 18.2, demonstrated potent in vivo efficacy in gastric cancer patient-derived xenografts","volume":"82","author":"Chen","year":"2022"},{"key":"B54","unstructured":"An open-label, multicenter phase II clinical study to evaluate the efficacy, safety, and tolerability of the LM-302 combination with other anti-tumor treatment in subjects with CLDN18.2-positive advanced gastro-intestinal cancer\n          \n          \n          2023"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.911459","article-title":"Receptor guanylyl cyclase C and cyclic GMP in health and disease: perspectives and therapeutic opportunities","volume":"13","author":"Prasad","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00280-023-04507-w","article-title":"A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C","volume":"91","author":"Kim","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-2474","article-title":"Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies","volume":"22","author":"Almhanna","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0439-y","article-title":"Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C","volume":"35","author":"Almhanna","year":"2017","journal-title":"Invest New Drugs"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"MAbs"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113328","article-title":"Trop2: jack of all trades, master of none","volume":"12","author":"Lenart","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"key":"B62","unstructured":"A phase I-II, first-in-human study of SKB264 in patients with locally advanced unresectable \/metastatic solid tumors who are refractory to available standard therapies\n          \n          \n          2019"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an anti-trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug Chem"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-16-0219","article-title":"Combining ABCG2 inhibitors with IMMU-132, an anti-trop-2 antibody conjugate of SN-38, overcomes resistance to SN-38 in breast and gastric cancers","volume":"15","author":"Chang","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B65","unstructured":"A phase II, multicentre, open-label, master protocol to evaluate the efficacy and safety of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced\/metastatic solid tumours\n          \n          \n          2022"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8365","article-title":"High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol Lett"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2017.10.034","article-title":"Nectin-4 promotes gastric cancer progression via the PI3K\/AKT signaling pathway","volume":"72","author":"Zhang","year":"2018","journal-title":"Hum Pathol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12951-024-02521-5","article-title":"A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer","volume":"22","author":"Wu","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217900","article-title":"Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates","volume":"630","author":"Yazdi","year":"2025","journal-title":"Cancer Lett"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01312","article-title":"Therapeutic implications of epidermal growth factor receptor (EGFR) in the treatment of metastatic gastric\/GEJ cancer","volume":"10","author":"Adashek","year":"2020","journal-title":"Front Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of safety of treatment with anti-epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors: A phase 1 nonrandomized clinical trial","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol"},{"key":"B72","unstructured":"A phase II clinical study to evaluate the efficacy and safety of MRG003 in EGFR-positive, HER2-negative advanced gastric cancer\n          \n          \n          2022"},{"key":"B73","unstructured":"A phase II clinical study to evaluate the efficacy and safety of SI-B003 monotherapy, BL-B01D1+SI-B003 combination therapy and BL-B01D1+PD-1 monoclonal antibody in patients with locally advanced or metastatic esophageal cancer, gastric cancer, colorectal cancer and other gastrointestinal tumors\n          \n          \n          2023"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.14670\/HH-23.1541","article-title":"The MUC gene family: their role in the diagnosis and prognosis of gastric cancer","volume":"23","author":"Senapati","year":"2008","journal-title":"Histol Histopathol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2711301","article-title":"Antibody-drug conjugates targeting tumor-specific mucin glycoepitopes","volume":"27","author":"Brassard","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-19-0826","article-title":"An antibody-drug conjugate targeting MUC1-associated carbohydrate CA6 shows promising antitumor activities","volume":"19","author":"Nicolazzi","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99880","article-title":"Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate","volume":"3","author":"Panchamoorthy","year":"2018","journal-title":"JCI Insight"},{"key":"B78","unstructured":"Phase 1\/2, open-label, multicenter, first-in-human study of DS-3939a in subjects with advanced solid tumors\n          \n          \n          2023"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108988","article-title":"Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer","volume":"110","author":"Shao","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-16-3127","article-title":"Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"Rios-Luci","year":"2017","journal-title":"Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgac063","article-title":"SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1","volume":"1","author":"Tomabechi","year":"2022","journal-title":"PNAS Nexus"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-334667","article-title":"Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy","volume":"75","author":"Sheng","year":"2026","journal-title":"Gut"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102284","article-title":"Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan","volume":"53","author":"Pourjamal","year":"2025","journal-title":"Transl Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1194","article-title":"Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells","volume":"9","author":"Sato","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241271913","article-title":"HER2 becomes a novel survival biomarker for gastric cancer patients: a pooled analysis","volume":"16","author":"Cheng","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012683","article-title":"Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy","volume":"13","author":"Lim","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202657","article-title":"Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival","volume":"68","author":"He","year":"2015","journal-title":"J Clin Pathol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s10120-013-0236-z","article-title":"Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors","volume":"17","author":"Jacome","year":"2014","journal-title":"Gastric Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-026-02577-x","article-title":"Spatial single-cell multi-omics characterization of the tumor microenvironment heterogeneity by HER-2 expression status in gastric cancer","volume":"25","author":"Peng","year":"2026","journal-title":"Mol Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"17648","DOI":"10.1038\/s41598-024-68411-w","article-title":"Heterogeneity of claudin 18.2 expression in metastatic gastric cancer","volume":"14","author":"Choi","year":"2024","journal-title":"Sci Rep"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-01034-7","article-title":"A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data","volume":"23","author":"Chen","year":"2020","journal-title":"Gastric Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.06.009","article-title":"Drug independence and the curability of cancer by combination chemotherapy","volume":"8","author":"Pomeroy","year":"2022","journal-title":"Trends Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/srao.2003.50002","article-title":"The mechanism of action of radiosensitization of conventional chemotherapeutic agents","volume":"13","author":"Lawrence","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.4_suppl.295","article-title":"Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced\/metastatic HER2+ gastric cancer (GC)\/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03","volume":"40","author":"Janjigian","year":"2022","journal-title":"J Clin Oncol"},{"key":"B98","article-title":"A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier","volume":"31","author":"Fujimori","year":"1990","journal-title":"J Nucl Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-1725","article-title":"Spatiotemporal quantification of HER2-targeting antibody-drug conjugate bystander activity and enhancement of solid tumor penetration","volume":"30","author":"Wei","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3892\/or.2013.2547","article-title":"Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model","volume":"30","author":"Yamashita-Kashima","year":"2013","journal-title":"Oncol Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-20-3822","article-title":"Transient competitive inhibition bypasses the binding site barrier to improve tumor penetration of trastuzumab and enhance T-DM1 efficacy","volume":"81","author":"Bordeau","year":"2021","journal-title":"Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B103","unstructured":"A phase 1b\/2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in adult participants with HER2-expressing gastric cancer (DESTINY-Gastric-03)\n          \n          \n          2020"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-026-04246-x","article-title":"Combining an anti-HER2 antibody-drug conjugate with an anti-nectin-4 antibody-drug conjugate enhances efficacy in breast cancer and gastric cancer models","volume":"26","author":"Yazdi","year":"2026","journal-title":"Cancer Cell Int"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2018.10.001","article-title":"Drawing lessons from the clinical development of antibody-drug conjugates","volume":"30","author":"Lyon","year":"2018","journal-title":"Drug Discov Today Technol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1928576\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:29:57Z","timestamp":1790155797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1928576\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":106,"alternative-id":["10.3389\/fimmu.2026.1928576"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1928576","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1928576"}}